Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalpiciclib + Adebrelimab in SMARCA4-deficient Advanced Solid Tumors
ChiCTR2600121890Phase 2Not yet recruiting
- Sponsor
- Chongqing University Cancer Hospital
- Start
- Apr 2026
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dalpiciclib and adebrelimab in Nonhematologic neoplasms, sponsored by Chongqing University Cancer Hospital. Primary endpoints: Maximum tolerated dose (MTD) and Objective response rate (ORR). Planned start Apr 2026; status: not yet recruiting.
02
Drugs
dalpiciclibadebrelimab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on ChiCTR2600121890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600121890.